Mibolerone API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Mibolerone is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Mibolerone or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Mibolerone API 3704-09-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Mibolerone. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Mibolerone 
Synonyms:
(7α,17β)-17-hydroxy-7,17-dimethylestr-4-en-3-one , 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one , 7α-17α-dimethyl-19-nortestosterone , Mibolerona , Miboleronum  
Cas Number:
3704-09-4 
DrugBank number:
DB11429 
Unique Ingredient Identifier:
9OGY4BOR8D

General Description:

Mibolerone, identified by CAS number 3704-09-4, is a notable compound with significant therapeutic applications. Mibolerone is a potent anabolic steroid which is both higher affinity and more selective for the androgen receptor than metribolone.

Classification:

Mibolerone belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane, classified under the direct parent group Estrogens and derivatives. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Steroids and steroid derivatives class, specifically within the Estrane steroids subclass.

Categories:

Mibolerone is categorized under the following therapeutic classes: Estranes, Estrenes, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Testosterone and derivatives, Testosterone Congeners. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Mibolerone is a type of Hormonal Agents


Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.

Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.

Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.

As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.